Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 1c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q1 EPS of ($0.31), $0.01 worse than the analyst estimate of ($0.30).

“Our January 2018 financing puts us in a strong position to advance and expand our robust TIL product pipeline. We continue enrollment in our ongoing trials and have expanded our melanoma study to enroll an additional 25 patients. We are initiating investigation of TIL therapy in new indications as part of our collaboration with MD Anderson, and one of those studies investigating our LN-145 TIL product in patients with sarcomas and ovarian cancers, is now active,” said Dr. Maria Fardis, Ph.D., MBA, president and chief executive officer of Iovance Biotherapeutics. “We also recently received orphan-drug designation from the FDA for autologous tumor infiltrating lymphocytes for the treatment of patients with cervical cancer with a tumor size of greater than 2 cm in diameter.”

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Build-A-Bear Workshop (BBW) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY Guidance
• HealthEquity (HQY) Tops Q2 EPS by 5c ; Offers Guidance